Zdrowie i gospodarka · 06/05/2022
FDA Releases Revised Draft Guidance for Testosterone Products
The Food and Drug Administration (FDA) is releasing a revised draft guidance for industry regarding testosterone products, outlining requirements for demonstrating bioequivalence to support abbreviated new drug applications (ANDAs) for testosterone pellets.
Source: Federal Register — Food and Drug AdministrationOpen original release →